Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Able to provide informed consent
• Male and female 18 years and older
• DSM-5 diagnosis of opioid use disorder (for OUD group)
• Physically healthy i.e., no clinically unstable medical conditions
• Written informed consent and have capacity to consent and comply with study procedures
Locations
United States
Connecticut
Connecticut Mental Health Center, Clinical Neuroscience Research Unit
RECRUITING
New Haven
Contact Information
Primary
Anahita Bassir Nia, MD
anahita.bassirnia@yale.edu
203-974-7540
Backup
Abby Dewey
abigail.dewey@yale.edu
475-441-4190
Time Frame
Start Date: 2023-03-10
Estimated Completion Date: 2027-12-15
Participants
Target number of participants: 30
Treatments
Other: Healthy Volunteers
Healthy volunteers with no current or past major medical or psychiatric history
Other: Opioid Use Disorder
Patients diagnosed with opioid use disorder
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA)
Leads: Yale University